Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib plus tafasitamab for previously treated marginal zone lymphoma
2024-514122-23-00Phase 2Authorised
- Sponsor
- International Extranodal Lymphoma Study Group
- Start
- Oct 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of acalabrutinib and tafasitamab in marginal zone B-cell lymphoma (MZL), sponsored by International Extranodal Lymphoma Study Group. Primary endpoint: Complete response rate. Planned start Oct 2021; status: authorised.
02
Drugs
acalabrutinibtafasitamab
03
Conditions
marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on 2024-514122-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514122-23-00.